Positive News SentimentPositive NewsNASDAQ:OKUR OnKure Therapeutics (OKUR) Stock Price, News & Analysis $18.42 -0.58 (-3.05%) (As of 10/11/2024 ET) Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsTrends About OnKure Therapeutics Stock (NASDAQ:OKUR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OnKure Therapeutics alerts:Sign Up Key Stats Today's Range$17.22▼$19.2050-Day Range N/A52-Week Range$9.80▼$86.70Volume124,139 shsAverage Volume26,663 shsMarket Capitalization$61.52 millionP/E RatioN/ADividend YieldN/APrice Target$35.00Consensus RatingStrong Buy Company OverviewReneo Pharmaceuticals Inc.is a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Inc.is based in SAN DIEGO.Read More… Case study on my NKE trade (Ad)Now, I won’t lie, I’m pretty stinkin’ proud of my track record trading Gamma Pockets… After all, I thought I’d retired to a quiet life as a stay-at-home dad… my days at PIMCO were long behind me… But, after seeing this track record, Roger insisted I come out of retirement and share these trades with the world. So I’m gonna do that on Monday. At 1pm ET, Roger and I will finally share the Gamma Pockets Summit! At 1pm ET, Roger and I will finally share the Gamma Pockets Summit! Make sure your seat is saved H OnKure Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks73rd Percentile Overall ScoreOKUR MarketRank™: OnKure Therapeutics scored higher than 73% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingOnKure Therapeutics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageOnKure Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about OnKure Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OnKure Therapeutics are expected to grow in the coming year, from ($6.50) to ($3.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OnKure Therapeutics is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OnKure Therapeutics is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOnKure Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about OnKure Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for OKUR. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOnKure Therapeutics does not currently pay a dividend.Dividend GrowthOnKure Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for OKUR. News and Social Media3.6 / 5News Sentiment1.50 News SentimentOnKure Therapeutics has a news sentiment score of 1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for OnKure Therapeutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for OKUR on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, OnKure Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.90% of the stock of OnKure Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.98% of the stock of OnKure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OnKure Therapeutics' insider trading history. Receive OKUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OnKure Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address OKUR Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com OKUR Stock Analysis - Frequently Asked Questions How have OKUR shares performed this year? OnKure Therapeutics' stock was trading at $19.00 on January 1st, 2024. Since then, OKUR shares have decreased by 3.1% and is now trading at $18.42. View the best growth stocks for 2024 here. How do I buy shares of OnKure Therapeutics? Shares of OKUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today10/12/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OKUR CUSIPN/A CIKN/A Webreneopharma.com Phone858-283-0280FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$35.00 High Stock Price Target$35.00 Low Stock Price Target$35.00 Potential Upside/Downside+90.0%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($16.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-77,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-62.52% Return on Assets-56.36% Debt Debt-to-Equity RatioN/A Current Ratio57.86 Quick Ratio57.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$26.60 per share Price / Book0.69Miscellaneous Outstanding Shares3,340,000Free Float2,745,000Market Cap$61.52 million OptionableN/A Beta0.21 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:OKUR) was last updated on 10/12/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe Crypto Whisperer Just Sounded the AlarmThe 2024 Altcoin Eruption is Almost Here (Get in by Nov. 4) In late 2020, Ian King urged his readers to tak...Banyan Hill Publishing | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.